427 related articles for article (PubMed ID: 28251017)
1. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
Atilla E; Ataca Atilla P; Demirer T
Balkan Med J; 2017 Jan; 34(1):1-9. PubMed ID: 28251017
[TBL] [Abstract][Full Text] [Related]
2. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Chaudhry HM; Bruce AJ; Wolf RC; Litzow MR; Hogan WJ; Patnaik MS; Kremers WK; Phillips GL; Hashmi SK
Biol Blood Marrow Transplant; 2016 Apr; 22(4):605-616. PubMed ID: 26409924
[TBL] [Abstract][Full Text] [Related]
3. Defining the intensity of conditioning regimens: working definitions.
Bacigalupo A; Ballen K; Rizzo D; Giralt S; Lazarus H; Ho V; Apperley J; Slavin S; Pasquini M; Sandmaier BM; Barrett J; Blaise D; Lowski R; Horowitz M
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1628-33. PubMed ID: 19896087
[TBL] [Abstract][Full Text] [Related]
4. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lymphoid malignancies with non-myeloablative stem cell transplantation.
Seftel MD; Lavoie J; Barnett MJ; Conneally E
Hematology; 2002 Jun; 7(3):151-5. PubMed ID: 12243977
[TBL] [Abstract][Full Text] [Related]
8. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
9. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
12. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
Luger SM; Ringdén O; Zhang MJ; Pérez WS; Bishop MR; Bornhauser M; Bredeson CN; Cairo MS; Copelan EA; Gale RP; Giralt SA; Gulbas Z; Gupta V; Hale GA; Lazarus HM; Lewis VA; Lill MC; McCarthy PL; Weisdorf DJ; Pulsipher MA
Bone Marrow Transplant; 2012 Feb; 47(2):203-11. PubMed ID: 21441963
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic hematopoietic stem cell transplantation in elderly].
Castagna L; Blaise D; Furst S
Bull Cancer; 2011 Aug; 98(8):915-25. PubMed ID: 21835732
[TBL] [Abstract][Full Text] [Related]
14. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Georges GE; Storb R
Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
Carella AM
Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
[TBL] [Abstract][Full Text] [Related]
18. [Reduced intensity allogenic hematopoietic stem cell transplantation in children].
Paillard C; Lutz P; Michel G; Leverger G; Dalle JH; Demeocq F; Kanold J
Bull Cancer; 2011 May; 98(5):541-8. PubMed ID: 21576045
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.
Cremer B; Sandmaier BM; Bethge W; Lange T; Goede V; Holtick U; Hallek M; Hübel K
Onkologie; 2011; 34(12):710-5. PubMed ID: 22156452
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
